Study: HPV vaccine by age 21 a sound public health investment
USA Today, August 21, 2008
A new economic analysis shows that the HPV vaccine could be a good financial investment in public health if given to preadolescent girls and women up to age 21. Authors of the study measured the Gardasil vaccine's value by calculating the cost of giving one person an extra healthy year of life and balancing the expense of vaccinations with the benefits of avoiding cancer, death, and related expenses.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- 3 Traits Personality Assessments Can't Reveal
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Carondelet to Pay $35M to Settle Fraud Allegations
- CHS Hacked, 4.5M Patient Records Compromised